FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954687150> ?p ?o ?g. }

• W2954687150 endingPage "366" @default.
• W2954687150 startingPage "362" @default.
• W2954687150 abstract "Objective: Infliximab-treated patients with rheumatoid arthritis (RA) may respond insufficiently due to low serum infliximab (sIFX) levels, caused by anti-drug antibodies (ADAs). However, monitoring of sIFX and ADAs is not routinely implemented, and levels for optimal outcome have not been validated. We searched for predictors for sIFX < 0.2 μg/mL and ADA development in a randomized setting. Methods: In the SWEFOT trial, of 128 patients randomized to methotrexate + IFX therapy, 101 had serum samples at 3, 9, and 21 months that were analysed for sIFX [enzyme-linked immunosorbent assay (ELISA)] and ADAs [ELISA, and precipitation and acid dissociation (PandA) when sIFX > 0.2 μg/mL]. The primary and secondary outcome measures were low disease activity [LDA = 28-joint Disease Activity Score (DAS28) ≤ 3.2] and remission (DAS28 < 2.6). Baseline characteristics were assessed as potential predictors of sIFX < 0.2 μg/mL or ADA positivity, using logistic regression. Results: Categorization of sIFX levels into < 0.2, 0.2-2.9, 3.0-7.0, and > 7.0 μg/mL showed a dose-response association with LDA (30%, 64%, 67%, and 79%, respectively, p = 0.008) and remission (10%, 45%, 39%, and 66%, p = 0.004) at trial cessation (21 months). Female patients had sIFX < 0.2 μg/mL more often than males (35% vs 7%, p = 0.006), with a similar trend for rheumatoid factor (RF)-positive vs RF-negative patients (34% vs 16%, p = 0.059). ADA positivity showed similar patterns, also after adjustment for potential confounders (female sex: p = 0.050; RF positivity: p = 0.067). PandA captured four highly ADA-reactive patients with sIFX > 0.2 μg/mL, of whom three were ADA positive at other time-points, all with high DAS28 at follow-up. Conclusion: In early RA patients receiving IFX as a second-line agent, sIFX < 0.2 μg/mL and ADA development were associated with treatment failure and were more common in females, with a similar trend for RF positivity. Our findings support the use of therapeutic drug monitoring, and PandA in ADA-negative non-responders. Trial registration: SWEFOT NCT00764725 ( https://clinicaltrials.gov/ct2/show/NCT00764725 )." @default.
• W2954687150 created "2019-07-12" @default.
• W2954687150 creator A5009560105 @default.
• W2954687150 creator A5009874074 @default.
• W2954687150 creator A5012009272 @default.
• W2954687150 creator A5014041537 @default.
• W2954687150 creator A5024484324 @default.
• W2954687150 creator A5031662324 @default.
• W2954687150 creator A5041150149 @default.
• W2954687150 creator A5059695525 @default.
• W2954687150 creator A5085603352 @default.
• W2954687150 date "2019-06-27" @default.
• W2954687150 modified "2023-10-14" @default.
• W2954687150 title "Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis: results from the SWEFOT trial population" @default.
• W2954687150 cites W1090241203 @default.
• W2954687150 cites W1974735309 @default.
• W2954687150 cites W1992628263 @default.
• W2954687150 cites W2003835888 @default.
• W2954687150 cites W2017883234 @default.
• W2954687150 cites W2073393820 @default.
• W2954687150 cites W2097148639 @default.
• W2954687150 cites W2117738981 @default.
• W2954687150 cites W2166396307 @default.
• W2954687150 cites W2166771071 @default.
• W2954687150 cites W2516202125 @default.
• W2954687150 cites W2753022203 @default.
• W2954687150 cites W2897747244 @default.
• W2954687150 cites W798616579 @default.
• W2954687150 doi "https://doi.org/10.1080/03009742.2019.1602670" @default.
• W2954687150 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31244356" @default.
• W2954687150 hasPublicationYear "2019" @default.
• W2954687150 type Work @default.
• W2954687150 sameAs 2954687150 @default.
• W2954687150 citedByCount "18" @default.
• W2954687150 countsByYear W29546871502020 @default.
• W2954687150 countsByYear W29546871502021 @default.
• W2954687150 countsByYear W29546871502022 @default.
• W2954687150 countsByYear W29546871502023 @default.
• W2954687150 crossrefType "journal-article" @default.
• W2954687150 hasAuthorship W2954687150A5009560105 @default.
• W2954687150 hasAuthorship W2954687150A5009874074 @default.
• W2954687150 hasAuthorship W2954687150A5012009272 @default.
• W2954687150 hasAuthorship W2954687150A5014041537 @default.
• W2954687150 hasAuthorship W2954687150A5024484324 @default.
• W2954687150 hasAuthorship W2954687150A5031662324 @default.
• W2954687150 hasAuthorship W2954687150A5041150149 @default.
• W2954687150 hasAuthorship W2954687150A5059695525 @default.
• W2954687150 hasAuthorship W2954687150A5085603352 @default.
• W2954687150 hasBestOaLocation W29546871501 @default.
• W2954687150 hasConcept C126322002 @default.
• W2954687150 hasConcept C151956035 @default.
• W2954687150 hasConcept C168563851 @default.
• W2954687150 hasConcept C203014093 @default.
• W2954687150 hasConcept C2776232647 @default.
• W2954687150 hasConcept C2777138892 @default.
• W2954687150 hasConcept C2777575956 @default.
• W2954687150 hasConcept C2779134260 @default.
• W2954687150 hasConcept C2781059491 @default.
• W2954687150 hasConcept C2908647359 @default.
• W2954687150 hasConcept C71924100 @default.
• W2954687150 hasConcept C77350462 @default.
• W2954687150 hasConcept C90924648 @default.
• W2954687150 hasConcept C99454951 @default.
• W2954687150 hasConceptScore W2954687150C126322002 @default.
• W2954687150 hasConceptScore W2954687150C151956035 @default.
• W2954687150 hasConceptScore W2954687150C168563851 @default.
• W2954687150 hasConceptScore W2954687150C203014093 @default.
• W2954687150 hasConceptScore W2954687150C2776232647 @default.
• W2954687150 hasConceptScore W2954687150C2777138892 @default.
• W2954687150 hasConceptScore W2954687150C2777575956 @default.
• W2954687150 hasConceptScore W2954687150C2779134260 @default.
• W2954687150 hasConceptScore W2954687150C2781059491 @default.
• W2954687150 hasConceptScore W2954687150C2908647359 @default.
• W2954687150 hasConceptScore W2954687150C71924100 @default.
• W2954687150 hasConceptScore W2954687150C77350462 @default.
• W2954687150 hasConceptScore W2954687150C90924648 @default.
• W2954687150 hasConceptScore W2954687150C99454951 @default.
• W2954687150 hasIssue "5" @default.
• W2954687150 hasLocation W29546871501 @default.
• W2954687150 hasLocation W29546871502 @default.
• W2954687150 hasLocation W29546871503 @default.
• W2954687150 hasLocation W29546871504 @default.
• W2954687150 hasOpenAccess W2954687150 @default.
• W2954687150 hasPrimaryLocation W29546871501 @default.
• W2954687150 hasRelatedWork W19323031 @default.
• W2954687150 hasRelatedWork W2014971425 @default.
• W2954687150 hasRelatedWork W2015976341 @default.
• W2954687150 hasRelatedWork W2083125534 @default.
• W2954687150 hasRelatedWork W2137485620 @default.
• W2954687150 hasRelatedWork W2245926129 @default.
• W2954687150 hasRelatedWork W2319957449 @default.
• W2954687150 hasRelatedWork W2376796343 @default.
• W2954687150 hasRelatedWork W2379436644 @default.
• W2954687150 hasRelatedWork W2397189434 @default.
• W2954687150 hasVolume "48" @default.
• W2954687150 isParatext "false" @default.
• W2954687150 isRetracted "false" @default.
• W2954687150 magId "2954687150" @default.

• next